Prashant Tiwari – författare

As research continues to uncover the complex causes of Alzheimer's disease, a deeper understanding of its cellular and molecular mechanisms is essential for developing effective therapies. Cellular and Molecular Mechanisms in Alzheimer's Disease Therapeutics, a two volume set, provides a comprehensive examination of the processes driving disease onset and progression, bringing together leading experts to illuminate key pathways, therapeutic targets, and emerging treatment strategies. Volume 1: Cellular Mechanisms explores the cellular mechanisms underlying Alzheimer's disease-such as synaptic dysfunction, neuroinflammation, mitochondrial impairment, and protein aggregation-while highlighting their therapeutic implications, including personalized medicine, blood-brain barrier dynamics, and micro RNA-based approaches. Volume 2: Molecular Mechanisms examines AD at the molecular level-covering protein aggregation, cellular dysfunction, and neuroinflammation-while integrating emerging therapies, personalized approaches, and global research efforts to bridge fundamental mechanisms with clinical applications.

As research continues to uncover the complex causes of Alzheimer's disease, a deeper understanding of its cellular and molecular mechanisms is essential for developing effective therapies. Cellular and Molecular Mechanisms in Alzheimer's Disease Therapeutics, a two volume set, provides a comprehensive examination of the processes driving disease onset and progression, bringing together leading experts to illuminate key pathways, therapeutic targets, and emerging treatment strategies. Volume 1: Cellular Mechanisms explores the cellular mechanisms underlying Alzheimer's disease-such as synaptic dysfunction, neuroinflammation, mitochondrial impairment, and protein aggregation-while highlighting their therapeutic implications, including personalized medicine, blood-brain barrier dynamics, and micro RNA-based approaches. Volume 2: Molecular Mechanisms examines AD at the molecular level-covering protein aggregation, cellular dysfunction, and neuroinflammation-while integrating emerging therapies, personalized approaches, and global research efforts to bridge fundamental mechanisms with clinical applications.

As research continues to uncover the complex causes of Alzheimer's disease, a deeper understanding of its cellular and molecular mechanisms is essential for developing effective therapies. Cellular and Molecular Mechanisms in Alzheimer's Disease Therapeutics, a two volume set, provides a comprehensive examination of the processes driving disease onset and progression, bringing together leading experts to illuminate key pathways, therapeutic targets, and emerging treatment strategies. Volume 1: Cellular Mechanisms explores the cellular mechanisms underlying Alzheimer's disease-such as synaptic dysfunction, neuroinflammation, mitochondrial impairment, and protein aggregation-while highlighting their therapeutic implications, including personalized medicine, blood-brain barrier dynamics, and micro RNA-based approaches. Volume 2: Molecular Mechanisms examines AD at the molecular level-covering protein aggregation, cellular dysfunction, and neuroinflammation-while integrating emerging therapies, personalized approaches, and global research efforts to bridge fundamental mechanisms with clinical applications.

As research continues to uncover the complex causes of Alzheimer's disease, a deeper understanding of its cellular and molecular mechanisms is essential for developing effective therapies. Cellular and Molecular Mechanisms in Alzheimer's Disease Therapeutics, a two volume set, provides a comprehensive examination of the processes driving disease onset and progression, bringing together leading experts to illuminate key pathways, therapeutic targets, and emerging treatment strategies. Volume 1: Cellular Mechanisms explores the cellular mechanisms underlying Alzheimer's disease-such as synaptic dysfunction, neuroinflammation, mitochondrial impairment, and protein aggregation-while highlighting their therapeutic implications, including personalized medicine, blood-brain barrier dynamics, and micro RNA-based approaches. Volume 2: Molecular Mechanisms examines AD at the molecular level-covering protein aggregation, cellular dysfunction, and neuroinflammation-while integrating emerging therapies, personalized approaches, and global research efforts to bridge fundamental mechanisms with clinical applications.

Discover a groundbreaking path forward in the fight against dementia with this vital resource, which bridges the gap between costly drug discovery and the transformative potential of harnessing the immune system to finally target the underlying mechanisms of Alzheimer’s disease. Alzheimer’s disease, which is characterized by a progressive loss of memory and cognitive function, is the most prevalent type of dementia in adults. Despite being widespread, there is currently no permanent treatment for this condition. Current drugs provide only symptomatic relief with serious adverse consequences. The process of discovering new medications in this field is costly and time-consuming, so despite effort on the part of the scientific and pharmaceutical communities, few Alzheimer’s medications have been created. This book offers a comprehensive exploration of how the immune system can be harnessed to combat one of the most challenging neurodegenerative disorders of our time. It examines the scientific foundations of immunotherapy, including antibody-based strategies, vaccine development, and modulation of innate and adaptive immune responses. It highlights the interplay between amyloid and tau pathology, neuroinflammation, and microglial activation, providing readers with a clear understanding of the mechanisms driving therapeutic innovation. Beyond the laboratory, this volume bridges preclinical research with clinical applications, addressing safety, efficacy, and regulatory considerations. Case studies, emerging technologies, and future directions are presented to illustrate both the promise and the challenges of immunotherapy in Alzheimer’s care. Designed for neuroscientists, pharmacologists, clinicians, and biotechnology professionals, the book serves as a vital resource for those seeking evidence-based insights into cutting-edge therapeutic approaches that may transform the landscape of Alzheimer’s treatment.

Discover a groundbreaking path forward in the fight against dementia with this vital resource, which bridges the gap between costly drug discovery and the transformative potential of harnessing the immune system to finally target the underlying mechanisms of Alzheimer s disease. Alzheimer s disease, which is characterized by a progressive loss of memory and cognitive function, is the most prevalent type of dementia in adults. Despite being widespread, there is currently no permanent treatment for this condition. Current drugs provide only symptomatic relief with serious adverse consequences. The process of discovering new medications in this field is costly and time-consuming, so despite effort on the part of the scientific and pharmaceutical communities, few Alzheimer s medications have been created. This book offers a comprehensive exploration of how the immune system can be harnessed to combat one of the most challenging neurodegenerative disorders of our time. It examines the scientific foundations of immunotherapy, including antibody-based strategies, vaccine development, and modulation of innate and adaptive immune responses. It highlights the interplay between amyloid and tau pathology, neuroinflammation, and microglial activation, providing readers with a clear understanding of the mechanisms driving therapeutic innovation. Beyond the laboratory, this volume bridges preclinical research with clinical applications, addressing safety, efficacy, and regulatory considerations. Case studies, emerging technologies, and future directions are presented to illustrate both the promise and the challenges of immunotherapy in Alzheimer s care. Designed for neuroscientists, pharmacologists, clinicians, and biotechnology professionals, the book serves as a vital resource for those seeking evidence-based insights into cutting-edge therapeutic approaches that may transform the landscape of Alzheimer s treatment.

Discover a groundbreaking path forward in the fight against dementia with this vital resource, which bridges the gap between costly drug discovery and the transformative potential of harnessing the immune system to finally target the underlying mechanisms of Alzheimer s disease. Alzheimer s disease, which is characterized by a progressive loss of memory and cognitive function, is the most prevalent type of dementia in adults. Despite being widespread, there is currently no permanent treatment for this condition. Current drugs provide only symptomatic relief with serious adverse consequences. The process of discovering new medications in this field is costly and time-consuming, so despite effort on the part of the scientific and pharmaceutical communities, few Alzheimer s medications have been created. This book offers a comprehensive exploration of how the immune system can be harnessed to combat one of the most challenging neurodegenerative disorders of our time. It examines the scientific foundations of immunotherapy, including antibody-based strategies, vaccine development, and modulation of innate and adaptive immune responses. It highlights the interplay between amyloid and tau pathology, neuroinflammation, and microglial activation, providing readers with a clear understanding of the mechanisms driving therapeutic innovation. Beyond the laboratory, this volume bridges preclinical research with clinical applications, addressing safety, efficacy, and regulatory considerations. Case studies, emerging technologies, and future directions are presented to illustrate both the promise and the challenges of immunotherapy in Alzheimer s care. Designed for neuroscientists, pharmacologists, clinicians, and biotechnology professionals, the book serves as a vital resource for those seeking evidence-based insights into cutting-edge therapeutic approaches that may transform the landscape of Alzheimer s treatment.

Alzheimer’s disease (AD) stands as a profound and growing global health concern, characterized by progressive neurodegeneration and cognitive decline. As research into the underlying causes of AD advances, it becomes clear that a deeper understanding of its molecular mechanisms is crucial for the development of effective therapeutic interventions. This new two-volume set, Cellular and Molecular Mechanism in Alzheimer’s Disease Therapeutics, presents a detailed exploration of the cellular and molecular processes that drive the onset and progression of Alzheimer’s disease. The volume brings together leading experts who offer insights into the intricate cellular and molecular pathways involved in AD pathology as well as potential therapeutic targets and innovative treatment strategies.Volume 1: Cellular Mechanism in Alzheimer’s Disease Therapeutics presents a detailed and up-to-date exploration of the cellular processes involved in AD, with an emphasis on their implications for therapeutic interventions. The book offers a comprehensive understanding of how various cellular mechanisms, such as synaptic dysfunction, neuroinflammation, mitochondrial impairment, and protein aggregation, contribute to the pathology of disease. Topics include blood-brain barrier dysfunction in AD, personalized medicine approaches based on genetic profiling, microRNAs in the management of disease, and more.Volume 2: Molecular Mechanism in Alzheimer’s Disease Therapeutics provides a comprehensive understanding of the disease at a molecular level, from the misfolding and aggregation of amyloid-beta and tau proteins to the disruptions in cellular homeostasis, mitochondrial dysfunction, and neuroinflammation. The volume presents some emerging tools and novel therapeutics and also discusses pharmacological modulation of neurodegenerative disorders, behavioral intervention and cognitive training in AD management, customizing therapies to individual genetic and molecular characteristics, ethical considerations in clinical trials and research, international efforts in AD research and treatment, and more. This volume bridges the gap between molecular research and therapeutic applications, shedding light on the latest findings related to disease mechanisms, such as oxidative stress, synaptic alterations, and the role of neuroinflammatory pathways.Unlike other texts, these two volumes integrate the latest research on biomarkers, drug development, and innovative treatment strategies, offering a comprehensive and up-to-date resource. The unique focus on both fundamental science and practical therapeutic applications makes this two-volume set an invaluable guide for researchers, clinicians, and students aiming to advance their understanding and treatment of disease. By focusing on the cellular and molecular insights into this disease, these volumes pave the way for inspiring novel therapeutic approaches that address the root causes of neurodegeneration.

As research continues to uncover the complex causes of Alzheimer’s disease, a deeper understanding of its cellular and molecular mechanisms is essential for developing effective therapies. Cellular and Molecular Mechanisms in Alzheimer’s Disease Therapeutics, a two volume set, provides a comprehensive examination of the processes driving disease onset and progression, bringing together leading experts to illuminate key pathways, therapeutic targets, and emerging treatment strategies. Volume 1: Cellular Mechanisms explores the cellular mechanisms underlying Alzheimer’s disease—such as synaptic dysfunction, neuroinflammation, mitochondrial impairment, and protein aggregation—while highlighting their therapeutic implications, including personalized medicine, blood–brain barrier dynamics, and micro RNA-based approaches. Volume 2: Molecular Mechanisms examines AD at the molecular level—covering protein aggregation, cellular dysfunction, and neuroinflammation—while integrating emerging therapies, personalized approaches, and global research efforts to bridge fundamental mechanisms with clinical applications.

As research continues to uncover the complex causes of Alzheimer’s disease, a deeper understanding of its cellular and molecular mechanisms is essential for developing effective therapies. Cellular and Molecular Mechanisms in Alzheimer’s Disease Therapeutics, a two volume set, provides a comprehensive examination of the processes driving disease onset and progression, bringing together leading experts to illuminate key pathways, therapeutic targets, and emerging treatment strategies. Volume 1: Cellular Mechanisms explores the cellular mechanisms underlying Alzheimer’s disease—such as synaptic dysfunction, neuroinflammation, mitochondrial impairment, and protein aggregation—while highlighting their therapeutic implications, including personalized medicine, blood–brain barrier dynamics, and micro RNA-based approaches. Volume 2: Molecular Mechanisms examines AD at the molecular level—covering protein aggregation, cellular dysfunction, and neuroinflammation—while integrating emerging therapies, personalized approaches, and global research efforts to bridge fundamental mechanisms with clinical applications.

This book offers a detailed exploration of G-protein-coupled receptors (GPCRs), key membrane proteins that mediate cellular responses to diverse signals. It covers GPCR activation, regulation, structural advances, technological innovations, and drug discovery, emphasizing their crucial roles in physiology and therapy. By integrating molecular insights with clinical applications, the book bridges basic science and translational research in GPCR biology.GPCRs function as vital cellular communication hubs by activating guanine nucleotide-binding proteins (G proteins) to transduce extracellular signals into intricate intracellular pathways. These signaling cascades regulate processes such as cell growth, gene expression, and intercellular communication, crucial for maintaining cellular homeostasis. Disruptions in GPCR signaling are linked to diverse pathologies, making them prime targets for therapeutic intervention.The book begins with GPCR structure and activation mechanisms, followed by signaling networks and receptor regulation. It then covers breakthroughs in structural biology and cutting-edge research technologies. Drug discovery strategies, including allosterism and biased signaling, are explored next. Systems biology and molecular pathologies provide deeper insights into GPCR functions and diseases. The final chapters focus on cellular toxicity, preclinical to clinical drug development, and future research challenges.This resource is designed for researchers and scientists in molecular pharmacology, cell biology, and drug discovery, as well as graduate and postgraduate students. Pharmaceutical industry professionals, educators, trainees, and healthcare professionals engaged in GPCR-targeted therapies will also find this book an essential guide to the latest advances and clinical applications.

This book offers a detailed exploration of G-protein-coupled receptors (GPCRs), key membrane proteins that mediate cellular responses to diverse signals. It covers GPCR activation, regulation, structural advances, technological innovations, and drug discovery, emphasizing their crucial roles in physiology and therapy. By integrating molecular insights with clinical applications, the book bridges basic science and translational research in GPCR biology.GPCRs function as vital cellular communication hubs by activating guanine nucleotide-binding proteins (G proteins) to transduce extracellular signals into intricate intracellular pathways. These signaling cascades regulate processes such as cell growth, gene expression, and intercellular communication, crucial for maintaining cellular homeostasis. Disruptions in GPCR signaling are linked to diverse pathologies, making them prime targets for therapeutic intervention.The book begins with GPCR structure and activation mechanisms, followed by signaling networks and receptor regulation. It then covers breakthroughs in structural biology and cutting-edge research technologies. Drug discovery strategies, including allosterism and biased signaling, are explored next. Systems biology and molecular pathologies provide deeper insights into GPCR functions and diseases. The final chapters focus on cellular toxicity, preclinical to clinical drug development, and future research challenges.This resource is designed for researchers and scientists in molecular pharmacology, cell biology, and drug discovery, as well as graduate and postgraduate students. Pharmaceutical industry professionals, educators, trainees, and healthcare professionals engaged in GPCR-targeted therapies will also find this book an essential guide to the latest advances and clinical applications.

Brain Tumour Drug Development provides a clear, multidisciplinary update on modern therapies for glioblastoma and other aggressive brain tumours. The book focuses on improving drug precision, crossing the blood-brain barrier, identifying biomarkers, designing effective trials, and accelerating translation from research to real patient care. Key Features Overcomes the blood-brain barrier using advanced delivery methods Improves drug penetration & specificity with nano and polymer-based systems Explores new therapies through immunotherapy, gene therapy, and personalised medicine Builds preclinical models & identifies biomarkers to support clinical success Designs regulatory-aligned clinical trial strategies for faster translation

Brain Tumour Drug Development provides a clear, multidisciplinary update on modern therapies for glioblastoma and other aggressive brain tumours. The book focuses on improving drug precision, crossing the blood-brain barrier, identifying biomarkers, designing effective trials, and accelerating translation from research to real patient care. Key Features Overcomes the blood-brain barrier using advanced delivery methods Improves drug penetration & specificity with nano and polymer-based systems Explores new therapies through immunotherapy, gene therapy, and personalised medicine Builds preclinical models & identifies biomarkers to support clinical success Designs regulatory-aligned clinical trial strategies for faster translation